luteal phase gonadotropin therapy effects human chorionic gonadotropin regimens OBJECTIVE Luteal phase abnormalities ovulation induction gonadotropins study effect modified human chorionic gonadotropin hCG regimen luteal phase gonadotropin treatment DESIGN Fifteen women private practice nonconception gonadotropin-stimulated cycles ovarian stimulation human menopausal gonadotropins hMG hCG single dose IU single dose divided doses IU week MAIN OUTCOME MEASURES Early midluteal late luteal estradiol progesterone levels luteal phase lengths median values intraquartile ranges IQR nonparametric analysis RESULTS Early midluteal levels similar regardless hCG regimen median late luteal level pg/mL IQR IQR split-dose regimen pg/mL IQR IQR single-dose regimen median late luteal level ng/mL IQR IQR split-dose regimen ng/mL IQR IQR single-dose regimen Median luteal phase lengths days IQR IQR split-dose regimen days IQR IQR single-dose regimen CONCLUSION hMG-stimulated cycles second dose hCG midluteal phase late luteal levels luteal phase 